TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32831109
Drug: Bang® Keto
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bang® Keto Coffee (130 kcal, 300 mg caffeine, 20 g protein)
Study: 32831109
Drug: Placebo (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (30 kcal, 11 mg caffeine, 1 g protein)
Study: 35040210
Drug: nano-curcumin 240
Approvals — FDA: no, EMA: no, PMDA: no
Description: nano-curcumin 240 mg/day for 7 days
Study: 615917691
Drug: Ranibizumab (RBZ)
Normalized name: Ranibizumab
DrugBank: Ranibizumab (DB01270)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ranibizumab (RBZ) 0.3 mg or 0.5 mg monthly injections
Study: 33047942
Drug: LUCAS 3
Normalized name: LEUCAS CEPHALOTES WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: LUCAS 3 mechanical CC device
Study: 35700341
Drug: E2027 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2027 (50 to 400 mg single doses)
Study: 35700341
Drug: E2027 (≥50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2027 (≥50 mg QD)
Study: 35700341
Drug: E2027 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2027 (50 mg QD)
Study: 35700341
Drug: E2027 (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: E2027 (single and multiple administration)
Study: 34403019
Drug: Hypnotic intervention
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hypnotic intervention designed to reduce hot flashes
Study: 33433656
Drug: Integrative oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative oncology treatment program (high adherence, attending ≥4 sessions during the first 6 weeks)
Study: 33433656
Drug: Integrative oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative oncology treatment program (high adherence)
Study: 33433656
Drug: Integrative oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Integrative oncology treatment program (low adherence)
Study: 32433835
Drug: Aripiprazole Lauroxil
Normalized name: Aripiprazole lauroxil
DrugBank: Aripiprazole lauroxil (DB14185)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aripiprazole Lauroxil (AL) - AL NanoCrystal Dispersion + oral aripiprazole 30 mg on day 1; AL 1,064 mg on day 8 and every 8 weeks thereafter
Study: 32433835
Drug: Paliperidone palmitate
Normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paliperidone palmitate (PP) - PP 234 mg on day 1; PP 156 mg on day 8 and then every 4 weeks thereafter
Study: 32565073
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg doxycycline administered within 72 hours after tick removal
Study: 33781979
Drug: Vein of
Normalized name: Sus scrofa vein preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vein of Marshall ethanol infusion
Study: 33130933
Drug: Implant Removal
Normalized name: Super Spot Remover
Approvals — FDA: no, EMA: no, PMDA: no
Description: Implant Removal (IR)
Study: 32829304
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) every 4 weeks (q4wk)
Study: 32829304
Drug: Intravitreal aflibercept
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal aflibercept injection (IAI) every 12 weeks (q12wk)
Study: 32997826
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of pain on maximum jaw opening and pain on palpation using DC/TMD
Study: 34843183
Drug: Spironolactone (12.5-25-50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spironolactone (12.5-25-50 mg/day)
Study: 33904027
Drug: Hydrochlorothiazide (HCT)
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide (HCT) 50 mg/day
Study: 32059924
Drug: Concurrent Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent Treatment of PTSD and Substance Use Disorders using Prolonged Exposure (COPE)
Study: 33345885
Drug: 17-hydroxyprogesterone caproate
Normalized name: 6α-Methyl-17α-hydroxyprogesterone acetate
Approvals — FDA: no, EMA: no, PMDA: no
Description: 17-hydroxyprogesterone caproate adherence (greater than 80% of intended injections)
Study: 32891604
Drug: Intensive therapy
Normalized name: Cortaid Intensive Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive therapy (HbA1c under 6.2%, blood pressure under 120/75 mmHg, low-density lipoprotein cholesterol under 80 mg/dL)
Study: 32891604
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (HbA1c under 6.9%, blood pressure under 130/80 mmHg, low-density lipoprotein cholesterol under 120 mg/dL)
Study: 33992287
Drug: Neurodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neurodynamic Therapy (NDT)
Study: 32534221
Drug: Zoledronate 5
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Zoledronate 5 mg infusion
Study: 36052897
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of amiodarone diluted in 50 mL of 5% dextrose over 10 min
Study: 36052897
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of 5% dextrose over 10 min
Study: 36052897
Drug: 1 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg/kg of amiodarone
Study: 36052897
Drug: 50 mL
Normalized name: TPN Bag 250 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mL of 5% dextrose
Study: 34589083
Drug: BLXA4 oral
Normalized name: BLXA4
DrugBank: BLXA4 (DB12133)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLXA4 oral rinse
Study: 34700571
Drug: 22-gene genomic
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 22-gene genomic classifier (GC) scores in patients receiving short-term or long-term androgen-deprivation therapy (ADT).
Study: 35072987
Drug: Spinach intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinach intake (both treatments)
Study: 32295504
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant tissue-type plasminogen activator
Study: 36215947
Drug: Vaccine +
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine + OPT-821
Study: 35040959
Drug: JNJ‐64530440 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐64530440 750 mg once daily
Study: 35040959
Drug: JNJ‐64530440 750
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ‐64530440 750 mg twice daily
Study: 34224930
Drug: GA-PCA (general
Approvals — FDA: no, EMA: no, PMDA: no
Description: GA-PCA (general anaesthesia with morphine patient-controlled analgesia)
Study: 36084645
Drug: Intensive lifestyle
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive lifestyle therapy (energy restriction and exercise)
Study: 32669521
Drug: Verbascox® (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbascox® (800 mg/day) for 2 weeks
Study: 32669521
Drug: Celecoxib (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (200 mg/day) for 2 weeks
Study: 33588150
Drug: Gem/afatinib (Gem:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gem/afatinib (Gem: 1000 mg/m2 weekly for three weeks followed by one week of rest, repeated every four weeks; Afatinib: 40 mg orally once daily)
Study: 33588150
Drug: Gem alone
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gem alone (1000 mg/m2 weekly for three weeks followed by one week of rest, repeated every four weeks)
Study: 32949542
Drug: Galcanezumab 120
Normalized name: Galcanezumab 120 mg/mL solution for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Galcanezumab 120 mg per month (with a 240 mg loading dose administered as two 120 mg injections) for 3 months
Study: 34372818
Drug: Combined group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined group (IV + topical-TXA)
Study: 33422006
Drug: Cumulative bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cumulative bevacizumab doses (various metrics including cumulative dose, quantiles of cumulative dose, standardized cumulative dose, Theoretical Blood Concentration (TBC), and Weighted Cumulative Exposure (WCE))
Study: 33422006
Drug: Cumulative bevacizumab
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cumulative bevacizumab doses
Study: 33226845
Drug: KOOS Activities
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: KOOS Activities of Daily Living (ADL)
Study: 32912157
Drug: Sildenafil (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25 mg TID for 3 months followed by 50 mg TID for 3 months; n=30)
Study: 33822654
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy services for 30 min twice weekly
Study: 33822654
Drug: Speech therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Speech therapy services for 15 min 4 times weekly
Study: 34320865
Drug: PECS-1 block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: PECS-1 block with 0.4 mL kg−1 0.25% bupivacaine
Study: 34320865
Drug: Infiltration anesthesia
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infiltration anesthesia with 0.4 mL kg−1 0.25% bupivacaine
Study: 34571187
Drug: Erector spinae
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erector spinae plane block (ESPB) with 30 mL of 0.375% ropivacaine
Study: 34571187
Drug: Sham block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham block with 30 mL of 0.9% saline
Study: 32664105
Drug: Conventional dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional dose group A (120 kVp, 150 mAs)
Study: 32664105
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group B (120 kVp, 50 mAs)
Study: 32664105
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group C (100 kVp, 50 mAs)
Study: 32664105
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose group D (100 kVp, 30 mAs)
Study: 34759247
Drug: Immediate surgery
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate surgery after chemotherapy (arm A)
Study: 35081010
Drug: Dexamethasone (4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (4 mg twice daily for 48 hours)
Study: 33640257
Drug: Lavender aromatherapy
Normalized name: LAVENDER
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lavender aromatherapy (inhalation for five minutes, three times a week)
Study: 35492241
Drug: LEAP2 infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEAP2 infusion
Study: 35492241
Drug: LEAP2 dosing
Normalized name: ALCOHOL 17.57 g in 30 mL TOPICAL LIQUID [Leap Frog Fresh HAND SANITIZER]
Approvals — FDA: no, EMA: no, PMDA: no
Description: LEAP2 dosing in wild-type mice
Study: 33152443
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT)
Study: 33926724
Drug: Fault detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fault detection performance index based on stochastic robustness/sensitivity ratio; specific dosage and duration not mentioned.
Study: 33926724
Drug: Fault detection
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fault detection threshold setting algorithms using Randomized Algorithms; specific dosage and duration not mentioned.
Study: 32029684
Drug: Sequential group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential group (PCV13 and DTaP at visit 1, IIV4 at visit 2)
Study: 32243660
Drug: Pelvic floor
Normalized name: Tenscare Kegel Toner Pelvic Floor Trainer
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pelvic floor muscle training (PFMT) + Game therapy (GT)
Study: 35325969
Drug: Hypochloric acid
Normalized name: Hydrochloric Acid
DrugBank: Hydrochloric acid (DB13366)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypochloric acid (100 μg/mL)
Study: 35325969
Drug: Povidone iodine
Normalized name: POVIDONE IODINE
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Povidone iodine (50 mg/mL)
Study: 32459885
Drug: Opicapone 25
Normalized name: opicapone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 25 mg tablet
Study: 32459885
Drug: Opicapone 50
Normalized name: opicapone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 50 mg tablet
Study: 32459885
Drug: Opicapone 25
Normalized name: opicapone 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 25 mg capsule
Study: 32459885
Drug: Opicapone 50
Normalized name: opicapone 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Opicapone 50 mg capsule
Study: 34689288
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (oral prednisolone 60 mg daily with gradual taper-off to 35 mg/day and cyclosporine 3 mg/kg/day)
Study: 34689288
Drug: Corticosteroid therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid therapy (methylprednisolone 1000 mg for 3 days followed by oral prednisolone)
Study: 32598793
Drug: Enisamium iodide
Normalized name: enisamium iodide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enisamium iodide with symptomatic therapy
Study: 32598793
Drug: Symptomatic therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptomatic therapy only (Control)
Study: 35110688
Drug: THC (7.5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: THC (7.5, 15 mg)
Study: 33051039
Drug: Music Therapy-Based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music Therapy-Based Stress Reduction (MTSR)
Study: 33377716
Drug: Priligy (dapoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priligy (dapoxetine hydrochloride) 30 mg 1-3 hours before sexual activity combined with behavioral therapy and psychological counseling (30 minutes, once a month for two times)
Study: 33377716
Drug: Priligy (dapoxetine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Priligy (dapoxetine hydrochloride) 30 mg 1-3 hours before sexual activity
Study: 36412415
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of single agent, 3 weekly injection paclitaxel 175 mg/m2 as maintenance therapy
Study: 33919991
Drug: L-carnitine tartrate
DrugBank: Levocarnitine (DB00583)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: L-carnitine tartrate supplementation
Study: 33400778
Drug: Adjuvanted trivalent
Normalized name: Influenza, adjuvanted, trivalent, PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted trivalent influenza vaccine (aTIV)
Study: 36215334
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) + snail control
Study: 36215334
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) alone
Study: 36215334
Drug: Mass drug
Normalized name: Xenon, isotope of mass 129
DrugBank: Xenon Xe-129 (DB17386)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mass drug administration (MDA) + behavioral change interventions
Study: 32840412
Drug: Doxycycline (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Doxycycline (100 mg daily for seven days)
Study: 32840412
Drug: Roxithromycin (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Roxithromycin (300 mg daily for seven days)
Study: 32508327
Drug: Pridopidine 45
Normalized name: Pridopidine
DrugBank: Pridopidine (DB11947)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pridopidine 45 mg BID
Study: 32502243
Drug: High phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: High phosphorus intake (≥ 1375 mg/d)
Study: 32502243
Drug: Low phosphorus
Normalized name: Phosphorus
DrugBank: Phosphorus (DB14151)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low phosphorus intake (< 1100 mg/d)
Study: 34892575
Drug: Spatially Distributed
Normalized name: rosin partially dimerized glycerol ester
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spatially Distributed Sequential Stimulation (SDSS)
Study: 33693678
Drug: Presence of
Normalized name: Dna Plasmid Expressing Diphtheria Toxin Triggered By The Presence Of Oncofetal Gene H19
DrugBank: Inodiftagene vixteplasmid (DB16017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Presence of any majority DRM with <2 active drugs
Study: 36155982
Drug: Ultra-low-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultra-low-dose CT scans
Study: 36155982
Drug: Standard-dose CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose CT scans
Study: 33820636
Drug: Ringer's solution
Normalized name: Ringer's solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's solution (4°C)
Study: 32413673
Drug: CAG repeat
Normalized name: an antisense oligonucleotide that has been developed to target expanded CAG repeats in messenger ribonucleic acid (mRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CAG repeat polymorphism of the androgen receptor gene
Study: 35969885
Drug: Conjugated equine
Normalized name: Conjugated equine estrogens
DrugBank: Conjugated estrogens (DB00286)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conjugated equine estrogen 0.45 mg/d
Study: 35969885
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol 50 mg/d (patch replaced weekly)
Study: 33629110
Drug: Anifrolumab 1000
Normalized name: ANIFROLUMAB
DrugBank: Anifrolumab (DB11976)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Anifrolumab 1000 mg every 4 weeks
Study: 32952837
Drug: Good oral
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Good oral hygiene status
Study: 32594453
Drug: Liraglutide (L)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide (L) therapy at a final dose of 3.0 mg/day
Study: 32594453
Drug: Liraglutide (L)
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Liraglutide (L) therapy
Study: 34932102
Drug: All RSVpreF
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All RSVpreF formulations
Study: 34962176
Drug: Film therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Film therapy analysis (12 sessions, one session per week)
Study: 34684442
Drug: Monitored therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monitored therapy (n = 54; with an option of dose modification)
Study: 34684442
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (n = 55; 500 IU vitamin D standard therapy)
Study: 35381950
Drug: Thyroid-stimulating hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thyroid-stimulating hormone (TSH)
Study: 34294114
Drug: Intravenous nimodipine
Normalized name: Nimodipine
DrugBank: Nimodipine (DB00393)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous nimodipine 1–2 mg/h from the day before surgery until the fifth postoperative day and standard of care
Study: 39217559
Drug: Semaglutide 2.4
Normalized name: semaglutide 2.4 MG in 0.75 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Semaglutide 2.4 mg
Study: 32074268
Drug: Antibiotics (intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (intravenous ertapenem 1 g once daily for 3 days followed by oral levofloxacin 500 mg once daily and metronidazole 500 mg 3 times per day)
Study: 32074268
Drug: Antibiotics (with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotics (with subsequent appendectomy)
Study: 32074268
Drug: Successful antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Successful antibiotic therapy
Study: 32417345
Drug: 36 Gy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 36 Gy in 6 fractions, twice a week (arm 1)
Study: 616651858
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a injected subcutaneously three times weekly (IFN beta-1a SC tiw)
Study: 616651858
Drug: Interferon beta-1a
Normalized name: interferon beta-1a
DrugBank: Interferon beta-1a (DB00060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon beta-1a injected intramuscularly once weekly (IFN beta-1a IM qw)
Study: 32506992
Drug: EG1 -
Normalized name: Ethinyl Estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: EG1 - Treatment group designed to change sexual scripts for consensual sex
Study: 32506992
Drug: EG2 -
Normalized name: Ethinyl Estradiol and Gestodene
Approvals — FDA: no, EMA: no, PMDA: no
Description: EG2 - Treatment group designed to promote sexual self-esteem and challenge perceived realism of pornography
Study: 32506992
Drug: CG -
Normalized name: HCG - Human chorionic gonadotropin
Approvals — FDA: no, EMA: no, PMDA: no
Description: CG - Non-treatment control group
Study: 32000816
Drug: Subperiosteal cocktail
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subperiosteal cocktail injection
Study: 34182998
Drug: BUD/FORM DPI
Approvals — FDA: no, EMA: no, PMDA: no
Description: BUD/FORM DPI 400/12 μg
Study: 34724323
Drug: Localized microinjections
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Localized microinjections of tranexamic acid (4 mg/ml) plus Q-switched 1064 laser every 2 weeks
Study: 34724323
Drug: Oral tranexamic
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tranexamic acid 250 mg three times a day plus Q-switched 1064 laser every 2 weeks
Study: 32910831
Drug: HES 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130/0.4 at 1 mL/kg/h (group 1)
Study: 32910831
Drug: HES 130/0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: HES 130/0.4 at 2 mL/kg/h (group 2)
Study: 34958142
Drug: 10 mg/day
Normalized name: Adlarity 10 MG/Day Weekly Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/day montelukast (Group 2)